Deliver Your News to the World

Epigentek Develops a New Method of Measuring Global DNA Methylation


NEW YORK, Sep 29 - Epigentek Group Inc. today announced that it released the SuperSense™ Methylated DNA Quantification Kit to complete its line of methylated DNA quantification products ( The SuperSense™ kit fluorometrically measures global DNA methylation shifts. This new tool complements the company’s flagship product and colorimetric version of quantifying methylated DNA, the Methylamp™ Global DNA Methylation Quantification Ultra Kit.

Global DNA hypomethylation is likely caused by methyl-deficiency due to a variety of environmental influences and has been proposed as a molecular marker in multiple biological processes such as cancer. It is well demonstrated that the decrease in global DNA methylation is one of the most important characteristics of cancer. Thus the quantification of global methylation in cancer cells provides very useful information for detection and analysis of this disease.

By offering a kit-based method for such quantification, Epigentek makes an improvement over conventional methods (i.e. mass spectrometry, enzymatic degradation and analysis, immunohistostaining), overcoming limitations such as the need for special equipment, long protocols, low sensitivity, and radioactivity.

The new SuperSense™ kit is a fluorescence-based assay that can be completed in 3 easy-to-follow steps within 2.5 hours via a convenient 96-well plate format. The kit is extremely sensitive with the detection limit as low as 50 pg of methylated DNA, suitable for quantifying methylated DNA using a very small amount of DNA samples.

Epigentek also simultaneously released a fluorometric version of its EpiQuik™ DNA Methyltransferase Activity/Inhibition Assay Kit.

Epigentek’s products consistently achieves the fastest speeds and highest results in the epigenetic research kit market. In 2007, Epigentek formed a strategic partnership with Sigma-Aldrich to provide its epigenetic technologies, including DNA methylation and ChIP, to the St. Louis company and to further the studies of epigenetics.

About Epigentek Group Inc.
Epigentek Group Inc. is a biotechnology company that focuses on developing and providing innovative technology and products as a complete and systematic solution for epigenetics-related research and drug discovery. The company, particularly emphasizing speed and effectiveness in its technologies, has developed a comprehensive portfolio of more than 700 proprietary products specifically designed to make assays significantly more simple, fast, convenient and efficient than conventional methods. Visit our website at


 cancer research
 dna methylation
 assay kits

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.